Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morgane Rolland

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Plos Pathogens|September 4, 2020
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challengeKier Om, Dominic Paquin-Proulx, Maria Montero, et al.
Cell Host & Microbe|March 4, 2021
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodiesSamantha M Townsley, Gina C Donofrio, Ningbo Jian, et al.
Science Translational Medicine|July 17, 2015
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisitionHeather A Prentice, Georgia D Tomaras, Daniel E Geraghty, et al.
Journal of Translational Medicine|December 14, 2011
Definition of the viral targets of protective HIV-1-specific T cell responsesBeatriz Mothe, Anuska Llano, Javier Ibarrondo, et al.
The Journal of Clinical Investigation|November 11, 2021
Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infectionJulie L Mitchell, Justin Pollara, Kenneth Dietze, et al.
Journal of Virology|July 3, 2023
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus ActivityJaime L Jensen, Rajeshwer S Sankhala, Vincent Dussupt, et al.
Emerging Infectious Diseases|April 13, 2023
US National Institutes of Health Prioritization of SARS-CoV-2 VariantsSam Turner, Arghavan Alisoltani, Debbie Bratt, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV InfectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
The Journal of Clinical Investigation|March 18, 2020
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral reboundEvan M Cale, Hongjun Bai, Meera Bose, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Plos Pathogens|September 4, 2020
Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challengeKier Om, Dominic Paquin-Proulx, Maria Montero, et al.
Cell Host & Microbe|March 4, 2021
B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodiesSamantha M Townsley, Gina C Donofrio, Ningbo Jian, et al.
Science Translational Medicine|July 17, 2015
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisitionHeather A Prentice, Georgia D Tomaras, Daniel E Geraghty, et al.
Journal of Translational Medicine|December 14, 2011
Definition of the viral targets of protective HIV-1-specific T cell responsesBeatriz Mothe, Anuska Llano, Javier Ibarrondo, et al.
The Journal of Clinical Investigation|November 11, 2021
Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infectionJulie L Mitchell, Justin Pollara, Kenneth Dietze, et al.
Journal of Virology|July 3, 2023
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus ActivityJaime L Jensen, Rajeshwer S Sankhala, Vincent Dussupt, et al.
Emerging Infectious Diseases|April 13, 2023
US National Institutes of Health Prioritization of SARS-CoV-2 VariantsSam Turner, Arghavan Alisoltani, Debbie Bratt, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV InfectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
The Journal of Clinical Investigation|March 18, 2020
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral reboundEvan M Cale, Hongjun Bai, Meera Bose, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Pageof 12